E-cigarette and vape uses more prone to infection

Industry InsightInnovation
Jul.22.2022
E-cigarette and vape uses more prone to infection

Rima, a 27-year-old Saudi woman, holds her electronic cigarette as she vapes at a coffee shop in downtown Riyadh, a sign of the changing times in Saudi Arabia - Copyright AFP/File JOHN THYS

Read more: https://www.digitaljournal.com/tech-science/e-cigarette-and-vape-uses-more-prone-to-infection/article#ixzz7ZkXgRHcoUsers of nicotine products are more susceptible to contracting an infection. One research study identified an abundance of Porphyromonas (a genus of Gram-negative bacteria implicated in periodontal disease) and Veillonella (a different group of Gram-negatives associated with cases of osteomyelitis and endocarditis) in higher levels among vapers, suggesting that vaping alters the oral microbiome. The oral microbiome has an established relationship to overall health and it is the second and most diverse microbiota next to the gut, home to over 1,000 species of microbes.

 

Disruptions to this community can lead to health implications. Of particular concern is the bacterium Porphyromonas gingivalis. Enzymes produced by the bacterium can attack collagen.
 

Periodontal, or gum, disease is one of the most common infectious diseases worldwide. In its more severe forms, such as periodontitis, the condition causes loss of the bone that supports the teeth. In addition to gum disease, the bacterium has been linked to rheumatoid arthritis.

 

Ecosystem stability can be affected by two types of disturbances: long-term influences or “presses” and short-term effects or “pulses”. Furthermore, the researchers discovered that interleukin (IL)-6 and IL-1?, a pro-inflammatory cytokines which indicate inflammatory responses, were highly elevated in e-cigarette users when compared with non-users. In particular, epithelial cell-exposed e-cigarette aerosols were more susceptible for infection. This led to the assessment that e-cigarette users are more prone to infection. This occurs because alterations to the microbial landscape, which accompanies higher levels of proteins in vapers’ mouths, signals that the immune system is more likely to activate and produce inflammation. In turn this exponentially increases the likelihood for disease.

 

Additionally, sequencing based studies have shown that certain species of bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa) are more strongly associated with the development of a
lung community skewed towards loss of diversity. Concerningly, these organisms are associated with declining lung function. It appears that e-cigarette vapor can change the way the bacteria grow, by increasing volume and the area covered by the bacteria, which can lead to infections if untreated.
 

The association between the oral cavity and disease is complex, with the pathogenicity of chronic periodontal disease a factor of the complex interaction of microbial pathogens, host immune response, and genetic and environmental factors. The drawing in of chemical vapor adds to the environmental complexity and appears to be a microbiome altering factor. However, what stands out from research is the general trend that the majority of the metagenome in e-cigarette users was shared by more than the majority of users, which contrasts with smokers and non-smokers, who do not tend to share their bacterial and fungal composition.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30